Efavirenz

If you have been diagnosed with Mild Cognitive Impairment (MCI) or early onset Alzheimer’s disease, please consider our study. An FDA-approved antiretroviral HIV medication called Efavirenz will be given to participants to investigate if it can reduce cholesterol in the brain and alter the progression of Alzheimer’s disease.

Age: 55-85 and diagnosed with MCI or early-onset Alzheimer’s disease

Double-blind study for 20 weeks

Reimbursement: $25 per visit which totals $425

If you interested, please contact Lisa Quinn, PhD, NP at LWQuinn@mgh.harvard.edu or 617-724-4076